Last reviewed · How we verify

NCT07435727

Comparison of Speaking Valve Trial and Capping Trial for Tracheostomy Decannulation in Stroke Patients

Not yet recruiting NA Last updated 27 February 2026
What this trial tests

NA trial testing Passy-Muir Speaking Valve in Stroke in 120 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
1 April 2027
1 July 2027

Quick facts

Lead sponsorHongying Jiang, MD
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment120
Start date1 April 2026
Primary completion1 April 2027
Estimated completion1 July 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Hongying Jiang, MD

Who can join

Adults 18 to 80, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the efficacy and safety of the Speaking Valve trial versus the traditional Capping trial as indicators for tracheostomy decannulation in stroke patients. The trial is a prospective, multicenter, randomized, parallel-group, outcomes-assessor-blinded study with an exploratory crossover design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Passy-Muir Speaking Valve

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Hongying Jiang, MD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07435727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing